Submit Your Request Now
- Panel Features
- Panels List
- Workflow
- Why Creative Proteomics
- Demo
- Sample Requirements
- Case
- FAQ
What is the Olink Explore 3072 (8 Panel Combinations)
Customized panel for human
The Olink Explore 3072 (8 panel combinations) leverages Proximity Extension Assay (PEA) technology to analyze over 2,900 protein biomarkers in a single run, covering both well-characterized and novel research targets. Requiring just 1-6 µL of plasma or serum per sample, the platform processes 88 samples per batch, delivering high sensitivity with detection limits under 1 pg/mL and excellent reproducibility (<5% CV) via Normalized Protein Expression (NPX) standardization. Its modular design integrates eight specialized subpanels, enabling broad immunological profiling and focused pathway analysis. Rigorous quality control, including NIST-traceable reference materials, ensures reliable biomarker quantification for applications such as cancer research and systems biology studies.
Features of the pane
- Species: Designed exclusively for human proteome research.
- Proteins : 2900+-plex biomarker panel optimized for biological studies.
- Sample: Minimal input volume (1-6 µL) of plasma or serum.
- Readout: Protein quantification using NPX normalization technology.
- Platform: Proprietary Olink Signature Q100 analytical system.
List of 3072 Human Derived Biomarkers
Protein category
The Olink Explore 3072 (8 Panel combinations) analyzes 3072 protein biomarkers. The panel comprehensively analyzes key protein classes including: Catalytic enzymes and metabolic regulators, Cell surface receptors and ligand-binding molecules, Inflammatory mediators (cytokines/chemokines), Extracellular matrix and cell adhesion components, Intracellular signaling molecules, Immune checkpoint and modulation proteins, Tissue growth factors and their binding partners, Specialized functional proteins with diverse biological roles. (see Table. List of Olink Explore 3072 (8 Panel combination)). These targets include human proteins involved in mechanisms critical for cardiovascular diseases, neurological diseases, inflammation, and tumorigenesis, including angiogenesis, intercellular communication, metabolic regulation, programmed cell death, and proliferation/differentiation pathways. It reflects the physiological and pathological state of the body, plays an extremely important role in the clinical diagnosis of diseases, and has great research value.
Protein Functions
Biological process
Mainly related to cardiovascular system diseases, nervous system diseases, inflammation and tumor development.
Disease area
Related to metabolic, vascular, oncologic, immunologic, and neurologic domains.
The Application of Olink Explore 3072 (8 Panel Combinations).
The Olink Explore 3072 (8 Panel combinations) enables high-throughput analysis of 3072 protein biomarkers across multiple biological pathways, providing researchers with a comprehensive tool for:
- Large-scale discovery of protein networks involved in cancer biology and tumor microenvironment regulation;
- Systems-level investigation of immune response dynamics and host-pathogen interactions;
- Identification of potential biomarkers for patient stratification in translational research studies.
Workflow of Olink Proteomics
Why Creativ Proteomics
Comprehensive Proteome Coverage
Simultaneously analyzes 3,072 protein biomarkers across diverse biological pathways for large-scale discovery research.
Flexible Panel Design
Combines 8 specialized subpanels with customizable configurations for tailored research applications.
Multi-Pathway Insights
Enables cross-panel correlation studies to investigate biological crosstalk between different protein networks.
High-Resolution Biomarker Ratios
Enables cross-panel biomarker correlation studies (e.g., inflammatory + metabolic markers) for deeper mechanistic insights.
Demo Results of Olink Data
Differential proteomic expression in males and females with or without de novo HF plasma. (Qin, H, et al. 2025)
Sample Requirements
| Sample Type | Recommended Sample Size | Sample Quality | Pre-treatment and Storage | Sample Transport |
| Plasma/Serum/Body Fluid | Sample requirement: 40 µL. | 500–1000 μg/mL protein concentration. | Portion samples in sterile containers, -80°C storage | Transport sealed specimens with dry ice (-80°C). |
| Tissue | ||||
| Cells | ||||
| Exosomes | ||||
| Other |
Case Study
Proteomic profiling of neonatal herpes simplex virus infection on dried blood spots
Journal: Communications medicine
Year: 2024
- Background
- Methods
- Results
Neonatal herpes simplex virus (HSV) infection is life-threatening and often disseminates due to subtle symptoms and delayed treatment, with a mortality rate of up to 70-80%. Newborn screening using dried blood spot samples is one of the most effective preventive health measures implemented to date, but screening for herpes simplex virus has not yet been conducted.
This studied high-throughput multiplex proteomics of DBS samples collected 2-3 days after birth from a nationwide cohort of HSV-infected neonates (n = 53) and matched controls. Researchers measured 2941 proteins using the Olink Explore 3072 panel and proximity extension assay, and then determined the differential expression of the proteins through analysis of variance (ANOVA), post-hoc correction, and functional annotation.
The Olink Explore 3072 panel successfully quantified all 2,941 proteins in DBS samples, with matching variables and QC/PCA analyses revealing no case-control differences. Permutation tests confirmed strong ANOVA correlation (R²=0.9985), and post-hoc analysis identified significant pairwise differences: neonates with disseminated disease showed the most protein alterations versus controls (n=134, FDR<0.05; Fig1a), while CNS and SEM disease groups exhibited 27 and 22 differential proteins, respectively (Fig1b, c).
Figure 1. Differences in protein levels between newborns infected with herpes simplex virus and the control group. (Dungu, K. H. S., et al. 2024)
FAQs
What are the internal controls of Olink Explore? How are they used for data analysis?
Olink Explore includes three types of internal controls that join us in our analysis to monitor every step of the program.
- Incubation control: PEA detection of non-human proteins, monitoring potential changes at all steps, and used for data QC.
- Extended control: The antibody molecule is attached to the DNA oligonucleotide and is therefore always in close proximity. This controls the expansion, library preparation, and sorting steps, and is also used for data standardization purposes.
- Amplification control: A synthetic double-stranded amplicon that controls the preparation of libraries and the sequencing steps of the protocol, and is used for data QC.
Which sample types are compatible with Olink Explore?
Olink Explore is validated for human plasma and serum, with demonstrated compatibility for other samples like CSF. Contact support for additional sample type inquiries.
What are the main differences between proteomic sequencing using Olink technology and traditional DNA sequencing?
Olink uses NGS (next-generation sequencing) as a tool to measure the relative concentration of specific protein biomarkers in a sample. During sample and library preparation, short pieces of DNA with a unique sequence for each protein biomarker are generated. After sequencing, the number of counts (reads) of a particular DNA sequence is proportional to the original protein biomarker concentration.
References
- Qin, H., Tromp, J., Ter Maaten, J. M., et al. (2025). Clinical and Proteomic Risk Profiles of New-Onset Heart Failure in Men and Women. JACC. Heart failure, 13(3), 435–449. https://doi.org/10.1016/j.jchf.2024.09.022
- Dungu, K. H. S., Hagen, C. M., Bækvad-Hansen, M., et al. (2024). Proteomic profiling of neonatal herpes simplex virus infection on dried blood spots. Communications medicine, 4(1), 268. https://doi.org/10.1038/s43856-024-00711-8